Time-controlled drug delivery systems

Modern Pharmaceutics: Fifth Edition

Volumn 2-2, Issue , 2016, Pages 1-22

  Siepmann, Juergen ^a   Siepmann, Florence ^a  

^a UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84886547331     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (71)

1. Tanquary AC, Lacey RE, eds. Controlled Release of Biologically Active Agents. New York: Plenum Press, 1974.
2. Baker R., ed. Controlled Release of Biologically Active Agents. New York: John Wiley, 1987.
3. Langer RS, Wise DL, eds. Medical Applications of Controlled Release, Vol 1: Classes of Systems. Boca Raton: CRC Press, 1984.
4. Grieg NH. Optimizing drug delivery to brain tumors. Cancer Treat Rev 1987; 14:1-28.
5. Abott NJ, Romero IA. Transporting therapeutics across the blood-brain barrier. Mol Med Today 1996; 2:106-113.
6. Langer R. Polymeric delivery systems for controlled drug release. Chem Eng Commun 1980; 6: 1-48.
7. Langer R, Peppas NA. Chemical and physical structure of polymers as carriers for controlled release of bioactive agents: a review. Rev Macromol Chem Phys 1983; C23:61-126.
8. Rosen HB, Kohn J, Leong K, et al. Bioerodible polymers for controlled release systems. In: Hsieh D, ed. Controlled Release Systems: Fabrication Technology, Vol 2. Boca Raton: CRC Press, 1988:83-110.
9. Guse C, Koennings S, Kreye F, et al. Drug release from lipid-based implants: elucidation of the underlying mass transport mechanisms. Int J Pharm 2006; 314:137-144.
10. Kreye F, Siepmann F, Siepmann J. Lipid implants as drug delivery systems. Expert Opin Drug Deliv 2008; 5:291-307.
11. Herrmann S, Winter G, Mohl S, et al. Mechanisms controlling protein release from lipidic implants: effects of PEG addition. J Control Release 2007; 118:161-168.
12. Noyes AA, Whitney WR. Ueber die Aufloesungsgeschwindigkeit von festen Stoffen in ihren eigenen Loesungen. Z Physikal Chem 1897; 23:689-692.
13. Fan LT, Singh SK, eds. Controlled release. A Quantitative Treatment. Berlin: Springer-Verlag, 1989.
14. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev 2001; 48:139-157.
15. Siepmann J, Goepferich A. Mathematical modeling of bioerodible, polymeric drug delivery systems. Adv Drug Deliv Rev 2001; 48:229-247.
16. Peppas NA. Mathematical modeling of diffusion processes in drug delivery polymeric systems. In: Smolen VF, Ball L, eds. Controlled Drug Bioavailability, Vol 1. New York: John Wiley, 1984:203-237.
17. Vergnaud JM, ed. Liquid Transport Processes in Polymeric Materials. Englewood Cliffs: Prentice-Hall, 1991:26-29.
18. Vergnaud JM, ed. Controlled Drug Release of Oral Dosage Forms. Chichester: Ellis Horwood, 1993.
19. Siepmann J, Siepmann F. Mathematical modeling of drug delivery. Int J Pharm 2008; 364:328-343.
20. Siepmann J, Siepmann F, Florence AT. Local controlled drug delivery to the brain: mathematical modeling of the underlying mass transport mechanisms. Int J Pharm 2006; 314:101-119.
21. Fick A. Ueber Diffusion. Ann Phys 1855; 94:59-86.
22. Crank J, ed. The Mathematics of Diffusion. Oxford: Clarendon Press, 1975.
23. Cussler EL, ed. Diffusion: Mass Transfer in Fluid Systems. New York: Cambridge University Press, 1984.
24. Higuchi T. Physical chemical analysis of percutaneous absorption process from creams and ointments. J Soc Cosmet Chem 1961; 11:85-97.
25. Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspensions. J Pharm Sci 1961; 50:874-875.
26. Higuchi T. Mechanisms of sustained action mediation. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 1963; 52:1145-1149.
27. Colombo P. Swelling-controlled release in hydrogel matrices for oral route. Adv Drug Deliv Rev 1993; 11:37-57.
28. Doelker E. Water-swollen cellulose derivatives in pharmacy. In: Peppas NA, ed. Hydrogels in Medicine and Pharmacy, Vol 2. Boca Raton: CRC Press, 1986:115-160.
29. Siepmann J, Kranz H, Bodmeier R, et al. HPMC-matrices for controlled drug delivery: a new model combining diffusion, swelling and dissolution mechanisms and predicting the release kinetics. Pharm Res 1999; 16:1748-1756.
30. Siepmann J, Peppas NA. Hydrophilic matrices for controlled drug delivery: an improved mathematical model to predict the resulting drug release kinetics (the "sequential layer" model). Pharm Res 2000; 17:1290-1298.
31. Colombo P, Bettini R, Peppas NA. Observation of swelling process and diffusion front position during swelling in hydroxypropyl methyl cellulose (HPMC) matrices containing a soluble drug. J Control Release 1999; 61:83-91.
32. Colombo P, Bettini R, Santi P, et al. Swellable matrices for controlled drug delivery: gel-layer behaviour, mechanisms and optimal performance. Pharm Sci Technol Today 2000; 3:198-204.
33. Narasimhan B, Peppas NA. Disentanglement and reptation during dissolution of rubbery polymers. J Poly Sci Poly Phys 1996; 34:947-961.
34. Narasimhan B, Peppas NA. On the importance of chain reptation in models of dissolution of glassy polymers. Macromolecules 1996; 29:3283-3291.
35. Wright JC, Stevenson CL. Pumps/osmotic. In: Mathiowitz E, ed. Encyclopedia of Controlled Drug Delivery, Vol 2. New York: John Wiley, 1999.
36. Perkins L, Peer C, Fleming V. Pumps/osmotic-alzet system. In: Mathiowitz E, ed. Encyclopedia of Controlled Drug Delivery, Vol 2. New York: John Wiley, 1999.
37. Bittner B, Thelly T, Isel H, et al. The impact of co-solvents and the composition of experimental formulations on the pump rate of the ALZET osmotic pump. Int J Pharm 2000; 205:195-198.
38. Goepferich A. Polymer degradation and erosion: mechanisms and applications. Eur J Pharm Biopharm 1996; 42:1-11.
39. Goepferich A, Langer R. Modeling of polymer erosion. Macromolecules 1993; 26:4105-4112.
40. Goepferich A. Mechanisms of polymer degradation and erosion. Biomaterials 1996; 17:103-114.
41. Goepferich A. Polymer bulk erosion. Macromolecules 1997; 30:2598-2604.
42. von Burkersroda F, Schedl L, Goepferich A. Why degradable polymers undergo surface erosion or bulk erosion. Biomaterials 2002; 23:4221-4231.
43. Lee PI. Diffusional release of a solute from a polymeric matrix-approximate analytical solutions. J Membr Sci 1980; 7:255-275.
44. Goepferich A, Langer R. Modeling monomer release from bioerodible polymers. J Control Release 1995; 33:55-69.
45. Goepferich A, Langer R. Modeling of polymer erosion in three dimensions-rotationally symmetric devices. AIChE J 1995; 41:2292-2299.
46. Goepferich A. Bioerodible implants with programmable drug release. J Control Release 1997; 44:271-281.
47. Goepferich A. Erosion of composite polymer matrices. Biomaterials 1997; 18:397-403.
48. Siepmann J, Faisant N, Benoit JP. A new mathematical model quantifying drug release from bioerodible microparticles using Monte Carlo simulations. Pharm Res 2002; 19:1887-1895.
49. Faisant N, Siepmann J, Richard J, et al. Mathematical modeling of drug release from bioerodible microparticles: effect of gamma-irradiation. Eur J Pharm Biopharm 2003; 56:271-279.
50. Siepmann J, Elkharraz K, Siepmann F, et al. How autocatalysis accelerates drug release from PLGA-based microparticles: a quantitative treatment. Biomacromolecules 2005; 6:2312-2319.
51. Klose D, Siepmann F, Elkharraz K, et al. How porosity and size affect the drug release mechanisms from PLGA-based microparticles. Int J Pharm 2006; 314:198-206.
52. Shenderova A, Burke TG, Schwendeman SP. The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins. Pharm Res 1999; 16:241-248.
53. Brunner A, Maeder K, Goepferich A. pH and osmotic pressure inside biodegradable microspheres during erosion. Pharm Res 1999; 16:847-853.
54. Li L, Schwendeman SP. Mapping neutral microclimate pH in PLGA microspheres. J Control Release 2005; 101:163-173.
55. Lu L, Garcia CA, Mikos AG. In vitro degradation of thin poly(DL-lactic-co-glycolic acid) films. J Biomed Mater Res 1999; 46:236-244.
56. Brem H, Mahaley MS, Vick NA, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991; 74:441-446.
57. Grossman SA, Reinhard C, Colvin OM, et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 1992; 76:640-647.
58. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995; 345:1008-1012.
59. Brem H, Ewend MG, Piantadosi S, et al. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neurooncol 1995; 26:111-123.
60. Moses MA, Brem H, Langer R. Advancing the field of drug delivery taking aim at cancer. Cancer Cell 2003; 4:337-341.
61. Green SB, Byar DP, Walker MD, et al. Comparisons of carmustine, procarbazine, and high dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 1983; 67:121-132.
62. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Glidel wafers) in patients with primary malignant glioma. Neuro Oncology (serial online) 2003, 5, Doc. 02-023. Available at: http://neuro-oncology.mc.duke. edu.
63. Westphal M, Ram Z, Riddle V, et al. Gliadel wafer in initial surgery for malignant glioma: long term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006; 148:269-275.
64. Menei P, Montero-Menei C, Venier MC, et al. Drug delivery into the brain using poly(lactide-co-glycolide) microspheres. Expert Opin Drug Deliv 2005; 2:363-376.
65. Tatard VM, Venier-Julienne MC, Benoit JP, et al. In vivo evaluation of pharmacologically active microcarriers releasing NGF and conveying PC12 cells. Cell Transplant 2004; 13: 573-583.
66. Tatard VM, Venier-Julienne MC, Saulnier P, et al. Pharmacologically active microcarriers: a tool for cell therapy. Biomaterials 2005; 26:3727-3737.
67. Tatard VM, Menei P, Benoit JP, et al. Combining polymeric devices and stem cells for the treatment of neurological disorders: a promising therapeutic approach. Curr Drug Targets 2005; 6: 81-96.
68. Tatard VM, Sindji L, Branton JG, et al. Pharmacologically active microcarriers releasing glial cell line-derived neurotrophic factor: survival and differentiation of embryonic dopaminergic neurons after grafting in hemiparkinsonian rats. Biomaterials 2007; 28:1978-1988.
69. Santini JT, Cima MJ, Langer R. A controlled-release microchip. Nature 1999; 397:335-338.
70. Wang PP, Frazier J, Brem H. Local drug delivery to the brain. Adv Drug Deliv Rev 2002; 54: 987-1013.
71. Li Y, Shawgo RS, Tyler B, et al. In vivo release from a drug delivery MEMS device. J Control Release 2004; 100:211-219.